Bremelanotide Reviews: Real Women Share Their First-Dose Experience

She has already read the FDA approval letter. What she wants now is something the trial papers cannot tell her: what does it actually feel like to inject Vyleesi for the first time? The answer is messier than the marketing or the critics let on.

Bremelanotide, sold as Vyleesi, was approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women. We covered the mechanism and the FDA story in depth, and we wrote separately about the off-label male audience. This article sits with the patient corpus from Drugs.com, WebMD, r/Menopause, and the published trial questionnaires, and reconstructs what actually happens during an evening with bremelanotide.

That corpus is contradictory. Some women describe a dose that "changed my life." Others describe being bedridden for fifteen hours after a single 1.75 mg injection. Both are reporting honestly. The question is which side of that distribution you are likely to land on.

What Women Actually Say After Their First Vyleesi Dose

Pull up the Drugs.com user reviews for Vyleesi and the average lands at 7.2 out of 10 across 39 reviews, with 64% reporting positive and 21% reporting negative. That number sounds reassuring until you click through to WebMD's separate corpus of 37 reviews, where the average drops to 2.8 out of 5 and 23 of 37 patients gave the lowest possible satisfaction rating. Same drug, same indication, different verdicts.

The disagreement is not a measurement problem. It is a pharmacological reality. Bremelanotide produces dramatic responses in some women, no measurable response in others, and a punishing physical experience in a third group that frequently overlaps with the second.

The same first dose gets described as "I have never had an orgasm that seemed to go on forever" by a 48-year-old breast cancer survivor on r/Menopause, and as "the worst experience of my life — never been more sick, puking non-stop" by a 35-44 year old on WebMD. Neither is exaggerating. Their bodies responded differently to the same molecule.

One narrative thread shows up across forums but not on any official adverse-event list: a powerful urge to stretch. "I started to feel the need to stretch my whole body out, and oh did it feel good," writes one Drugs.com reviewer. "Restless legs were maddening and continued throughout the night," writes another on WebMD. The sensation lands somewhere between pleasant warmup and debilitating restlessness depending on the user.

The First 90 Minutes: A Timeline From Real User Reports

The Vyleesi label tells women to inject at least 45 minutes before sexual activity. The pharmacology supports that window: bremelanotide reaches its maximum plasma concentration about an hour after subcutaneous injection, with a 2.5-hour half-life and 100% subcutaneous bioavailability. What the label does not capture is how the body experiences those 45 minutes.

0 to 5 minutes: The autoinjector clicks. Most women report the needle is so thin they cannot feel it. A common immediate sensation is warmth or heat to the face. "I flushed immediately," one user wrote. "Right away, I was nauseous, but it went away within a few minutes," wrote another.

10 to 30 minutes: Visible flushing peaks. According to the WebMD drug monograph, nausea typically begins around the 30-minute mark. Some users report needing to sit in front of a fan with a cold rag. Others report sneezing fits, runny nose, or a cough.

30 to 60 minutes: The label cites about a two-hour nausea duration. Some women describe it as mild and manageable. Others — including many who took anti-emetics like Zofran beforehand — describe vomiting that lasts for hours.

60 to 90 minutes: According to the label, this is when arousal effects should begin. According to the patient corpus, this is usually when nothing has happened yet. Multiple users on Drugs.com report waiting two hours or more before feeling anything. A r/Menopause user described waiting two hours and hearing from others that onset can take up to six.

For some women, the response shows up only the next morning. One Drugs.com reviewer put it bluntly: "It did not take effect the same day for me, it hit me the next day." Another described falling asleep, then waking at 3 a.m. with what she called an "insatiable sexual urge." This delayed-onset pattern matters because it changes how you plan an evening. The 45-minute label suggests dinner-out timing. The patient corpus suggests staying home and being prepared for the drug to show up on its own schedule.

The Trial Outcomes That Matter to Her

Bremelanotide's approval rests on two phase 3 trials called RECONNECT, jointly enrolling 1,267 premenopausal women across two identically designed studies. Both coprimary endpoints were patient-reported outcomes — the women themselves answered the questions that determined whether the drug worked.

The first endpoint was the Female Sexual Function Index Desire Domain (FSFI-D), a five-item subscale where women rate sexual desire over four weeks. The second was item 13 of the Female Sexual Distress Scale Desire/Arousal/Orgasm version (FSDS-DAO), which asks how bothered the woman feels by her low desire.

On the FSFI desire domain, the integrated effect across both trials was +0.35 versus placebo (P less than .001). On the FSDS-DAO distress score, the integrated effect was -0.33 (P less than .001). Both numbers are real, both come from a properly randomized double-blind trial, and both convinced the FDA.

The harder question is what those numbers mean to the woman holding the autoinjector. The Greenjournal extension paper reports the minimum clinically important difference for FSFI-D as +0.6 and for FSDS-DAO item 13 as -1.0. By that yardstick, the integrated trial effect of +0.35 falls below the threshold considered meaningful at the individual level. The distress effect also falls short.

That gap fuels the most prominent academic critique. The psychologist Glen Spielmans has argued in published commentaries that effect sizes this small are "unimpressive" and "likely not clinically meaningful." A team of HSDD trialists including James Simon and Anita Clayton responded in Sex Med that small numerical gains can still be meaningful when the underlying disorder substantially impairs quality of life. They note HSDD has a quality-of-life burden comparable to diabetes or chronic back pain.

Even on the most favorable read, Vyleesi does not produce the kind of universal effect that something like a beta-blocker does for blood pressure. Harvard Health summarized the FDA registration data: about 25% of women on bremelanotide reported some increase in desire versus 17% on placebo, an absolute treatment effect of about 8 percentage points. Distress improved in 35% on drug versus 31% on placebo, a 4-point gap. The number of satisfying sexual events did not change at all.

That is not a reason to skip the drug. It is a reason to set expectations close to that data, not close to the manufacturer's "164% increase in desire" framing, which makes the same effect sound dramatic by computing percentage of percentage rather than absolute change.

The Side-Effect Reality: Why One in Four Walks Away

The trial AE numbers are stark. In RECONNECT, 40.0% of women on bremelanotide reported nausea versus 1.3% on placebo. Flushing was 20.3% versus 0.3%. Headache, 11.3% versus 1.9%. Those come straight from the published trial.

The 40% nausea figure is a population statistic over 24 weeks, not a single-dose probability. The manufacturer's own dose-by-dose breakdown looks different: 21% of women report nausea after the first dose, dropping to 3% after the second and 2% after the third. If that pattern holds, the brutal first-dose experience may not repeat.

But not always. The patient corpus contains women whose dose-2 experience was worse than dose-1: "The first dose, I experienced some nausea, but not bad. I decided to try another dose. Big mistake. It was like the 24-hour flu." That pattern shows up too often to dismiss.

The cardiovascular category is most underweighted in casual discussion. Vyleesi causes a transient rise in blood pressure and a transient drop in heart rate. According to the FDA labeling summarized in GoodRx's pharmacist review, those changes peak 2 to 4 hours after a dose and resolve within 12 hours. The mean change is small, but Vyleesi is contraindicated in uncontrolled hypertension and known cardiovascular disease, and the label tells women to seek attention if their systolic crosses 180 or diastolic crosses 120.

Hyperpigmentation is the side effect most likely to be skimmed in the consult and most consequential long-term. Bremelanotide is a melanocortin receptor agonist; one of those receptors (MC1R) governs melanin production. Patches of darkened skin can appear on the face, breasts, and gums. Risk is higher with daily use and darker baseline skin. The label, GoodRx, and the manufacturer's site all carry the same blunt sentence: skin darkening may not go away, even after you stop using Vyleesi.

How often does someone actually quit? The cleanest number comes from the 52-week open-label extension of RECONNECT, where women previously on placebo started bremelanotide for the first time. Roughly 24 to 26% of those new starters discontinued for adverse events, compared with 11 to 19% among already-tolerant continuers. One in four is not a small fraction.

Responder, Partial Responder, Nonresponder

Reading the patient corpus, three rough buckets emerge.

The strong responders describe an experience that goes well beyond a 0.35-point questionnaire change. A 47-year-old perimenopausal woman on r/Menopause writes that two hours after injection, "I kept stimulating my clit by accident just by crossing my legs or tightening my pelvic muscles." She also describes a "Part II" of the effect 12 to 20 hours later — a delayed second wave that shows up frequently. Strong responders typically describe sensitivity rather than libido. The drug does not manufacture craving; it manufactures responsiveness, which becomes craving when met with stimulation.

The partial responders describe something subtler. "I waited for something to happen. I guess I was expecting a wave of desire to rush over me, but it was more subtle. About an hour later, I did want to have sex — which never happens for me anymore." This bucket lines up most closely with the average woman in the trial.

The nonresponders get nothing. "Vyleesi doesn't work at all, I'm 37 and really no libido. I tried it twice, it does absolutely nothing." Or, more painfully: "I never felt any increase in libido because I was so sick."

Nobody yet has a good predictive model for which bucket a given woman lands in. The trial enrolled women with acquired generalized HSDD of at least six months in stable monogamous relationships, with at least two prior years of normal sexual function. Women with chronic illnesses, mental health conditions, or those on antidepressants, opioids, or BP medications were excluded, leaving an evidence gap for many women who realistically come to the consult.

The label has a built-in nonresponder rule: if Vyleesi does not help after eight weeks, stop. That is the closest thing to a clean off-ramp, and it is worth holding to. Stacking doses to chase an effect that is not materializing does not increase the chance of response. It increases the chance of hyperpigmentation and cardiovascular changes.

The Cost Conversation Most Women Have at the Pharmacy

Cost is the part of the conversation that most often surprises women who walk into a consult excited. The sticker price for a 4-dose pack of Vyleesi has historically been quoted in the hundreds of dollars per dose; one medspa source still references $250 per injection. Insurance coverage is uneven. One Drugs.com reviewer wrote about logging into her insurance portal and seeing a $1,700 charge before the pharmacy clarified that her actual copay was $98.

The current pricing is more forgiving than the sticker suggests. Vyleesi is now distributed primarily through BlinkRx. A 4-dose box is listed at $99 for uninsured patients (about $25 per dose), and most commercially insured patients pay $0 with copay assistance. The catch: women on Medicaid, TRICARE, or other government-funded programs are not eligible for that copay assistance.

The FDA explicitly limits Vyleesi to one dose per 24 hours and no more than eight doses per month. The drug is not designed to be a daily medication. It is designed for occasional use, and the eight-dose monthly cap exists in part to limit cumulative hyperpigmentation risk.

How to Prepare for Your First Dose

The patient corpus contains enough hard-won practical wisdom that it is worth distilling. None of this replaces a conversation with your prescribing clinician.

Pick a night when nothing is on the calendar the next morning. Multiple women in the corpus describe still feeling residual effects 12 to 24 hours after injection — sometimes the desired residual sensitivity, sometimes lingering nausea or fatigue. The manufacturer's own guidance is to "start with their first dose on a day when they don't have big plans." Treat that literally.

Consider an anti-emetic and time it correctly. Evidence is mixed on whether Zofran helps — some women say it did not touch their symptoms — but if your prescriber offers it, the patient consensus favors taking it 30 to 60 minutes before the injection rather than concurrently. The reasoning: the anti-emetic needs time to take effect before bremelanotide enters the bloodstream.

Consider a solo trial run. This is the most quietly common piece of advice from women who report a positive overall experience. Use the first dose alone, lying down, observing what happens, without performance pressure for a partner. As one r/Menopause poster put it: "Definitely do a test run the first time to familiarize yourself with the process, work through any anxiety, and to give your body time to adjust to the medication."

Get a baseline blood pressure reading before injecting. The transient post-dose rise is small on average, but the FDA wants any woman whose post-dose systolic crosses 180 or diastolic crosses 120 to seek immediate medical attention. You cannot tell whether you have crossed those thresholds without a measurement.

Use birth control if you can become pregnant. Animal studies suggest possible fetal harm; human data are insufficient. The label is unambiguous on this point.

Mentally separate the first dose from a verdict on the drug. Even women who became enthusiastic Vyleesi users often had imperfect first doses. The manufacturer's own nausea data — 21% to 3% to 2% across the first three doses — implies the same: dose one is not the dose that should determine your continued participation.

Frequently Asked Questions

Is Vyleesi the same as PT-141 sold by online compounding pharmacies?

The active ingredient — bremelanotide — is the same molecule. Vyleesi is the FDA-approved branded product, manufactured under federal Good Manufacturing Practice rules and sold at the 1.75 mg dose in single-use autoinjectors. PT-141 sold through compounding pharmacies and gray-market peptide vendors is the same chemical but is not subject to the same purity or sterility verification, and dose accuracy varies. The mechanism is identical; the manufacturing oversight is not.

How long should I wait before trying Vyleesi a second time if the first dose did nothing?

The label allows up to one dose per 24 hours and up to eight doses per month, so you can technically retry the next day. Several patient reports describe the first dose producing little or no effect and the second or third dose producing a clear response. The label's harder rule: if you have used Vyleesi as directed for eight weeks and still see no improvement, stop using the medication.

Can I drink alcohol on Vyleesi?

The Vyleesi label does not impose the alcohol restriction that the daily flibanserin (Addyi) label does. The manufacturer markets Vyleesi as "safe to use with alcohol." That said, Vyleesi raises blood pressure transiently, alcohol affects blood pressure too, and some patient reports describe feeling worse on the combination. Sensible moderation rather than absolute abstention is the practical line.

Why doesn't Vyleesi increase the number of satisfying sexual events in the trial data?

Bremelanotide moved the desire and distress scores statistically; it did not move the count of satisfying sexual events. One interpretation is that the drug primarily affects the brain's responsiveness to sexual stimuli rather than the frequency of intercourse. The drug should not be evaluated against a "more sex" benchmark; it should be evaluated against a "more interest in sex when sex happens" benchmark.

Is bremelanotide safe to use during perimenopause?

The FDA approval is specifically for premenopausal women with acquired, generalized HSDD. Postmenopausal use is off-label, and the trials excluded postmenopausal participants. Several r/Menopause threads document perimenopausal women using Vyleesi successfully, often as a bridge while titrating hormone therapy. That use is a conversation with a clinician familiar with perimenopausal pharmacology, not a self-prescribed decision.